Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...
A total of 18 abstracts will be presented at AANEM and the MGFA scientific session, highlighting UCB's dedication to driving advancements in gMG treatment. These presentations will cover data on ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase ...
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia ...
Myasthenia Gravis Highlights From AANEM Data on therapeutic advances, including Fc receptor antagonists and complement inhibitors, top the myasthenia gravis highlights from AANEM 2022. Also reported ...
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients Oct. 29, 2025 11:00 AM ET argenx SE (ARGNF) ...
“Our latest data reflect argenx’ ambition to deliver transformational impact for all people living with MG globally with rapid and significant functional improvements sustained over time, regardless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results